UK markets closed
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • FTSE 250

    23,658.94
    +26.10 (+0.11%)
     
  • AIM

    1,275.74
    +3.60 (+0.28%)
     
  • GBP/EUR

    1.1711
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • BTC-GBP

    35,177.89
    +514.03 (+1.48%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • DOW

    34,584.88
    -166.44 (-0.48%)
     
  • CRUDE OIL

    71.96
    -0.65 (-0.90%)
     
  • GOLD FUTURES

    1,753.90
    -2.80 (-0.16%)
     
  • NIKKEI 225

    30,500.05
    +176.71 (+0.58%)
     
  • HANG SENG

    24,920.76
    +252.91 (+1.03%)
     
  • DAX

    15,490.17
    -161.58 (-1.03%)
     
  • CAC 40

    6,570.19
    -52.40 (-0.79%)
     

NFL BIOSCIENCES: ANALYST COVERAGE LAUNCHED WITH INVEST SECURITIES

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NFL BIOSCIENCES: ANALYST COVERAGE LAUNCHED WITH INVEST SECURITIES

  • Recommendation: BUY

  • Target share price: €4.90

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is today announcing the start of NFL Biosciences’ analyst coverage by Invest Securities, an independent financial services provider whose research activities are carried out by 12 professionals covering more than 120 companies in diverse sectors.

The coverage of NFL Biosciences follows the research agreement set up after its initial public offering on Euronext Growth Paris in June 2021. This analysis was carried out by Thibaut Voglimacci Stephanopoli, a specialist Health and MedTech stock analyst.

Available on NFL Biosciences’ website (“Investors” section), the analysis recommends buying the NFL Biosciences share, with a target share price of €4.90.

Closing share price prior to publication: €3.59

About de NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in Montpellier, France, whose most advanced botanical drug candidate is an aid to stop smoking. Known as NFL-101, this natural nicotine-free product, extracted from standard tobacco leaves, is protected by two patent families. NFL Biosciences aims to offer smokers who would like to stop a safe, natural solution that is effective over the long-term, with short-term personalized administration.
Alongside NFL-101, NFL Biosciences has various development projects focused on botanical drugs for the treatment of cannabis use disorder and alcoholism.
Learn more at http://www.nflbiosciences.com

NFL Biosciences’ shares are listed on Euronext Growth Paris. (FR0014003XT0 ALNFL)
Contacts
Bruno Lafont – info@nflbiosciences.com - +33 (0)4 11 93 76 67
Agence Calyptus – nflbio@calyptus.net - +33 (0)1 53 65 68 68

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting